Financial Performance - The company reported a revenue of HKD 28,008,000 for the six months ended September 30, 2025, a decrease of 9.1% compared to HKD 30,792,000 in the same period last year[5]. - The gross profit for the same period was HKD 12,270,000, representing a gross margin of approximately 43.8%[5]. - The company incurred a loss from continuing operations of HKD 459,709,000, compared to a profit of HKD 100,978,000 in the previous year[6]. - The company reported a total comprehensive loss of HKD 456,863,000 for the period, compared to a comprehensive income of HKD 103,910,000 in the previous year[6]. - The basic and diluted loss per share from continuing operations was HKD (19.09), compared to earnings of HKD 4.22 in the same period last year[6]. - The company reported a net loss of HKD 459,319,000 for the six months ended September 30, 2025, compared to a profit of HKD 101,459,000 in the same period of 2024[29]. - The company did not declare an interim dividend for the six months ending September 30, 2025, compared to no dividend declared for the same period in 2024[36]. Assets and Liabilities - Total assets decreased to HKD 1,098,039,000 from HKD 1,526,352,000 as of March 31, 2025, reflecting a decline of 28%[4]. - Current assets dropped significantly to HKD 641,436,000 from HKD 1,062,791,000, a decrease of 39.5%[4]. - The company's equity attributable to owners decreased to HKD 892,643,000 from HKD 1,334,542,000, a decline of 33.1%[4]. - The company’s total liabilities as of September 30, 2025, included trade payables of HKD 4,633,000, an increase from HKD 4,427,000 as of March 31, 2025[25]. - The total debt to total assets ratio was 0.14 as of September 30, 2025, compared to 0.09 on March 31, 2025[59]. Business Operations - The company has ceased its gene development business, focusing on its manufacturing and trading operations[8]. - The group operates in three main segments: manufacturing, trade, and gene development[10]. - Revenue from the manufacturing of pharmaceuticals for the six months ended September 30, 2025, was HKD 28,000,000, a decrease of 9.1% from HKD 30,772,000 in the same period of 2024[26]. - The company’s external customer revenue from the trading of pharmaceuticals was HKD 8,000 for the six months ended September 30, 2025, down from HKD 20,000 in 2024[26]. Investments and Financial Instruments - The convertible bond investment from Star Chain Group, originally issued at HKD 715,000,000, has been reclassified as other receivables due to non-conversion[15][20]. - The fair value of the convertible bond investment was HKD 915,436,000 as of March 31, 2025, but was reclassified to zero as of September 30, 2025[16][20]. - The fair value change of convertible bonds investment for the six months ended September 30, 2025, was a loss of HKD 442,729,000, compared to a gain of HKD 111,229,000 in the same period of 2024[30]. - The company recorded an unrealized loss of approximately HKD 442.7 million related to the fair value changes of the convertible bond investment during the first half of 2025[53]. Shareholder Activities - The company issued 160,000,000 new ordinary shares at a subscription price of HKD 0.097 per share, raising a total of HKD 15,520,000[23]. - Approximately 70% of the net proceeds will be allocated to startup costs in the healthcare sector, including product development and marketing, while the remaining 30% will be reserved for working capital[62]. - As of September 30, 2025, the net proceeds from the subscription had not yet been utilized[63]. - The number of share options available under the share option scheme as of September 30, 2025, was 239,000,000, representing about 10% of the issued shares prior to the recent subscription[66]. Employee and Operational Costs - The total employee costs for the six months ending September 30, 2025, amounted to HKD 9,848,000, a decrease of 9.9% from HKD 10,936,000 in the previous year[31]. - Sales costs for the same period were HKD 15,738,000, down 17.8% from HKD 18,980,000 in the prior year[31]. - The group’s administrative, sales, and distribution expenses totaled approximately HKD 16,400,000, an increase of about HKD 1,700,000 or 11.3% compared to HKD 14,800,000 in the prior period, driven by increased marketing and promotional expenses[42]. - Employee costs for the mid-year period amounted to approximately HKD 9,800,000, a decrease from HKD 10,900,000 in the previous period, primarily due to reduced performance-related bonuses[65]. Future Outlook and Strategic Plans - The company plans to commercialize its product in Q1 2026, but has revised the timeline to around Q3 2028 due to delays in patient recruitment and clinical trials[50]. - The company aims to explore new business opportunities in the healthcare sector, driven by factors such as an aging population and increasing consumer focus on preventive healthcare[64]. - The company plans to enter two new markets by the end of 2024, targeting a 30% market share[75]. Compliance and Governance - The interim financial data was approved for publication by the board on November 28, 2025[8]. - The audit committee has reviewed the unaudited interim financial information and confirmed compliance with current accounting practices in Hong Kong[72]. - The interim results announcement has been published on the Hong Kong Stock Exchange website and the company's website[73].
精优药业(00858) - 2026 - 中期业绩